REVOLADE FILM-COATED TABLET 25MG

Manufacturer
Novartis Pharmaceuticals Manufacturing LLC(SLOVENIA)

Registraction Number
MAL20102010ARZ

Content:
Revolade 25 mg Film-coated Tablet contains eltrombopag olamine, which is equivalent to 25 mg of eltrombopag as eltrombopag free acid.
Indications:

• Immune Thrombocytopenia (ITP): Used in adults and children aged 6 years and above who are refractory to other treatments (e.g., corticosteroids, immunoglobulins).
• Chronic Hepatitis C Virus (HCV) Infection: For the treatment of thrombocytopenia in adults where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy.
• Severe Aplastic Anemia (SAA): In combination with standard immunosuppressive therapy as first-line treatment for adults and adolescents aged 12 years and older.
• Acquired Severe Aplastic Anemia (SAA): In adults who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for hematopoietic stem cell transplantation.

• Dosage: The recommended starting dose is 50 mg once daily. For patients of East/Southeast Asian ancestry, the dose should be initiated at 25 mg once daily.
• Administration: Take the tablet orally with water. Swallow the tablet whole; do not crush or chew it.
• Precautions: Inform your doctor if you have any allergies, liver or kidney problems, or if you are pregnant or planning to become pregnant. Avoid taking with products containing polyvalent cations (e.g., calcium, magnesium) within 2 hours before or 4 hours after taking Revolade.
• Storage: Store below 30°C, away from moisture and heat.